Fatal Trichosporon fungemia in patients with hematologic malignancies

Suzuki, Kei; Nakase, Kazunori; Kyo, Taiichi; Kohara, Tadahiro; Sugawara, Yumiko; Shibazaki, Tetsunori; Oka, Kouji; Tsukada, Tetsuya; Katayama, Naoyuki

doi:10.1111/j.1600-0609.2010.01410.x

Cited by 107 publications

(79 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Amphotericin B † ± 5-flucytosine B-III In vitro susceptibility only to these two agents; in vitro resistance to all azoles and echinocandins 176,177 Trichosporon spp. Voriconazole C-III Preferred therapy but scarce data; in vitro resistance to fluconazole, 5-flucytosine and amphotericin B † reported 178,179 †Refers to amphotericin B deoxycholate and its lipid formulations. MIC, minimum inhibitory concentration.…”

Section: Resultsmentioning

confidence: 99%

Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014

Chen

Sorrell

Chang

et al. 2014

Internal Medicine Journal

View full text Add to dashboard Cite

Pathogenic yeast forms are commonly associated with invasive fungal disease in the immunocompromised host, including patients with haematological malignancies and patients of haemopoietic stem cell transplants. Yeasts include the Candida spp., Cryptococcus spp., Pneumocystis jirovecii and some lesser-known pathogens. Candida species remain the most common cause of invasive yeast infections (and the most common human pathogenic fungi). These guidelines present evidence-based recommendations for the antifungal management of established, invasive yeast infections in adult and paediatric patients in the haematology/oncology setting. Consideration is also given to the critically ill patient in intensive care units, including the neonatal intensive care unit. Evidence for 'preemptive' or 'diagnostic-driven antifungal therapy' is also discussed. For the purposes of this paper, invasive yeast diseases are categorised under the headings of invasive candidiasis, cryptococcosis and uncommon yeast infections. Specific recommendations for the management of Pneumocystis jirovecii are presented in an accompanying article (see consensus guidelines by Cooley et al. appearing elsewhere in this supplement).

show abstract

Section: Resultsmentioning

confidence: 99%

Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014

Chen

Sorrell

Chang

et al. 2014

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

“…Trichosporonosis is a life-threatening mycosis, particularly for patients with hematological malignancies with a poor prognosis. [7][8][9] T. asahii is also known as an antigen for summer-type hypersensitivity pneumonitis (SHP). In Japan, SHP is considered a type III or IV allergy that occurs mainly in summer from April to November.…”

mentioning

confidence: 99%

Growth Inhibition of an Opportunistic Yeast Pathogen Trichosporon asahii by Staphylococcus epidermidis

Ikeda

Ogasawara

Takatori

et al. 2017

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

In the co-culture of Staphylococcus epidermidis and Trichosporon asahii, a fungal pathogen, it was observed that live S. epidermidis inhibited the growth of T. asahii. Soluble active anti-T. asahii substances were speculated to be produced by S. epidermidis in culture medium. Using 1 H-and 13 C-NMR spectra and electron ionization-high resolution mass spectrometry (HR-negative-FAB-MS), we separated the active molecule and identified it as lactic acid. Commercially available L-lactic acid and D-lactic acid inhibited the growth of T. asahii. These results show that metabolites from bacterial populations are involved in the interactions of pathogenic fungi. The use of antibacterial agents to treat primary diseases could lead to the disruption of normal microbial communities and could cause opportunistic infections such as trichosporonosis.

show abstract

“…In the last few years, there has been an increase in the occurrence of onychomycosis associated with Trichosporon spp., especially caused by T. asahii, T. mucoides and T. inkin [45].…”

Section: Fusariosis: Fusariosisis Is Caused By Fusarium Species Inclumentioning

confidence: 99%

Update on Fungal Disease: From Establish Infection to Clinical Manifestation

Melo¹,

Scorzoni²,

Rossi³

et al. 2017

J Biotechnol Biomater

View full text Add to dashboard Cite

Fungal diseases have emerged as an important cause of morbidity and mortality, especially among immunocompromised patients. Pathogenic fungi have evolved an array of virulence factors to survive within the host and to outwit immune defenses. Fungi may cause a wide range of diseases in humans that range in extent from superficial to disseminated infections. Generally, the site of infections classifies the type of fungal disease, which can be divided into superficial, cutaneous, subcutaneous and systemic. In addition, the fungal virulence factors determine whether the infection will become established in the host. A primary pathogen may infect an immunologically normal host, whereas, an opportunistic pathogen requires some compromise of the host immune defenses in order for the infection to become established. This article covers the main fungi that are responsible for the increase of the fungal infections.Keywords: Fungal infections; Virulence; Yeast; Opportunistic infections; Endemic mycosis Fungal InfectionsFungal diseases have changed constantly in the last years. The virulence of these microorganisms has been adapted according to the human host, promoting a range of clinical manifestation. Several are the ways by which fungi promote a disease depending on human body part involved by the microorganism and the immunologic system of the host [1].In this review, we discuss the main fungal pathogens responsible for causing several diseases, highlighting on their virulence associate to clinical manifestation and the difficulty to accomplish the treatment. Superficial and cutaneous fungal diseasesSuperficial and cutaneous fungal infections are very common and occur worldwide affecting millions of people, especially immunocompromised patients. The most common types of these infections are dermatophytosis (tinea or ringworm), pityriasis versicolor (formerly tinea versicolor) and candidiasis (moniliasis). These occur by fungal invasion into the skin, keratinized tissues and mucous membranes [2]. Trichosporon and Fusarium species also cause superficial fungal infection, but also may be considered an invasive pathogen that may cause a systemic infection [3,4].Dermatophytosis: Dermatophytes are fungi that invade keratinized structures of humans and animals producing a condition called dermatophytosis or, more commonly, tinea [5,6]. These fungi belong to three main genera Trichophyton, Microsporum and Epidermophyton, of these T. rubrum is the most prevalent species worldwide [7,8]. The mechanisms of pathogenicity of these fungi are not yet well understood. There are several studies focusing on keratinolytic proteases (keratinases) produced by dermatophytes, but it is not known how these fungi regulate the use of these proteases to obtain nutrients from the stratum corneum substrate they invade, and whether there are additional roles of these proteins in adhesion and immunomodulation [9].To establish the infection, the contact of arthroconidia or hyphal fragmens with the host skin is essential. The fungi express spe...

show abstract

Fatal Trichosporon fungemia in patients with hematologic malignancies

Cited by 107 publications

References 30 publications

Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014

Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014

Growth Inhibition of an Opportunistic Yeast Pathogen <i>Trichosporon asahii</i> by <i>Staphylococcus epidermidis</i>

Update on Fungal Disease: From Establish Infection to Clinical Manifestation

Contact Info

Product

Resources

About